Evidence map›Paper›PMID 21915101›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2011

Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain.

Xiaoying Zhuang, Xiaoyu Xiang, William Grizzle, Dongmei Sun, Shuangqin Zhang, Robert C Axtell, Songwen Ju, Jiangyao Mu, Lifeng Zhang, Lawrence Steinman and 2 more

Erratum issuedOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 749 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
749citing papers in PubMed, 3 pooled it
21.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

749 citing papers in PubMed, 3 syntheses or guidelines pooled it, 1,326 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Current trends in exosomes as therapeutic drug delivery systems.Naunyn-Schmiedeberg's archives of pharmacology · 2026
    Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article

689 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Xiaoying ZhuangLouisville Veterans Administration Medical Center, Louisville, Kentucky, USA.
Xiaoyu Xiang
William Grizzle
Dongmei Sun
Shuangqin Zhang
Robert C Axtell
Songwen Ju
Jiangyao Mu
Lifeng Zhang
Lawrence Steinman
Donald Miller
Huang-Ge Zhang
University of Louisville · USUniversity of Alabama at Birmingham · USStanford University · USYangzhou University · CN

Funding

Curcumin reverses tumor exosomes-mediated inhibition of myeloid differentiationR01AT004294 · NCCIH · UNIVERSITY OF LOUISVILLE · PI ZHANG, HUANG-GE · 2007 to 2010
$1.4M
Breast tumor exosomal Jak3BP mediated immunosuppressionR01CA116092 · NCI · UNIVERSITY OF LOUISVILLE · PI ZHANG, HUANG-GE · 2005 to 2011
$1.3M
Age related ubiquitin defect on T-cell response to tumorR01CA107181 · NCI · UNIVERSITY OF LOUISVILLE · PI ZHANG, HUANG-GE · 2005 to 2009
$1.1M
lung tumor exosome-mediated inflammation promotes tumor progression and growthR01CA137037 · NCI · UNIVERSITY OF LOUISVILLE · PI ZHANG, HUANG-GE · 2009 to 2010
$616k
NCCIH NIH HHS R01 AT004294NCCIH NIH HHS R01AT004294NCI NIH HHS R01 CA107181NCI NIH HHS R01CA107181NCI NIH HHS R01 CA116092NCI NIH HHS R01CA116092NCI NIH HHS R01 CA137037NCI NIH HHS R01CA137037
6 · The paper itself

Abstract

In this study, exosomes used to encapsulate curcumin (Exo-cur) or a signal transducer and activator of transcription 3 (Stat3) inhibitor, i.e., JSI124 (Exo-JSI124) were delivered noninvasively to microglia cells via an intranasal route. The results generated from three inflammation-mediated disease models, i.e., a lipopolysaccharide (LPS)-induced brain inflammation model, experimental autoimmune encephalitis and a GL26 brain tumor model, showed that mice treated intranasally with Exo-cur or Exo-JSI124 are protected from LPS-induced brain inflammation, the progression of myelin oligodendrocyte glycoprotein (MOG) peptide induced experimental autoimmune encephalomyelitis (EAE), and had significantly delayed brain tumor growth in the GL26 tumor model. Intranasal administration of Exo-cur or Exo-JSI124 led to rapid delivery of exosome encapsulated drug to the brain that was selectively taken up by microglial cells, and subsequently induced apoptosis of microglial cells. Our results demonstrate that this strategy may provide a noninvasive and novel therapeutic approach for treating brain inflammatory-related diseases.

Indexed as

Drug CarriersExosomesAdministration, IntranasalAnimalsAnti-Inflammatory AgentsBrain NeoplasmsEncephalomyelitis, Autoimmune, ExperimentalHumansMiceMicrogliaAnti-Inflammatory AgentsDrug Carriers

Identifiers

PMID21915101
PMCPMC3188748
OpenAlexW2124304994

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.